JAMA
Original Investigation
April 8, 2024
Steven E.听Nissen,听MD; Kathy听Wolski,听MPH; Gerald F.听Watts,听MD, DSc; Michael J.听Koren,听MD; Henry听Fok,听MBBS, PhD; Stephen J.听Nicholls,听MBBS, PhD; David A.听Rider,听PhD; Leslie听Cho,听MD; Steven听Romano,听MD; Carrie听Melgaard,听MS; Curtis听Rambaran,听MBBS, MD
JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504
This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.
JAMA
Preliminary Communication
April 3, 2022
Steven E.听Nissen,听MD; Kathy听Wolski,听MPH; Craig听Balog,听BS; Daniel I.听Swerdlow,听MD, PhD; Alison C.听Scrimgeour,听MSc; Curtis听Rambaran,听MD; Rosamund J.听Wilson,听PhD; Malcom听Boyce,听MD; Kausik K.听Ray,听MD; Leslie听Cho,听MD; Gerald F.听Watts,听MD, PhD; Michael听Koren,听MD; Traci听Turner,听MD; Erik S.听Stroes,听MD, PhD; Carrie听Melgaard,听MS; Giles V.听Campion,听MD, PhD
free access
has multimedia
JAMA. 2022; 327(17):1679-1687. 10.1001/jama.2022.5050
This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein(a) and assessed associated changes in plasma concentrations of lipoprotein(a), compared with placebo, among individuals with elevated lipoprotein(a) levels and no known cardiovascular disease.